The primary catalyst is the ABTECT Phase 3 maintenance trial data expected in late Q2 2026, which will determine the NDA submission path for obefazimod in UC. The royalty certificate repurchase removes a future royalty overhang but incurred a one-time €43M expense. Monitor the maintenance trial results closely, as positive data could drive significant upside, while a miss would severely impact the stock.
Price Chart
Executive Summary
Abivax reported Q1 2026 financial results with a net loss of €48.5 million, improved from a €52.4 million loss in Q1 2025, driven by a €13.2 million increase in financial income from FX gains and fair value changes. Operating expenses rose 19% to €57.6 million, primarily due to a 26% increase in R&D spending to €49.5 million, partly offset by lower G&A costs. The company also reported positive three-year interim data from Study 108, showing 68% clinical remission at week 144 with no new safety signals, and completed the repurchase of all royalty certificates for $90 million in May 2026. Cash, cash equivalents, and short-term investments stood at €491.6 million as of March 31, 2026, providing runway into Q4 2027, with key catalysts including ABTECT Phase 3 maintenance trial results expected in late Q2 2026.
Key Facts
- Net loss for Q1 2026 was €48.5 million, compared to €52.4 million in Q1 2025, a 7% improvement.
- Operating expenses increased 19% to €57.6 million, driven by a 26% rise in R&D expenses to €49.5 million.
- Cash, cash equivalents, and short-term investments were €491.6 million as of March 31, 2026, with projected runway into Q4 2027.
- Three-year interim data from Study 108 showed 68% (88/130) of patients in clinical remission at week 144, with 80% completing the full evaluation.
- Repurchased all royalty certificates for $90 million (€76.5 million) on May 7, 2026, with an estimated €43.0 million expense to be recognized in Q2 2026.
- Top-line results from the ABTECT Phase 3 maintenance trial expected in late Q2 2026, with NDA submission planned for Q4 2026 subject to positive data.
- Phase 2b ENHANCE-CD trial topline data expected in Q4 2026.
Financial Impact
Net loss improved by €3.9 million to €48.5 million; operating loss widened by €9.0 million to €56.2 million; cash burn from operations was €50.5 million in Q1 2026.
Risk Factors
- Phase 3 maintenance trial failure would delay or prevent NDA submission and significantly impair the stock.
- Operating cash burn of €50.5 million per quarter, with no revenue, requires continued financing beyond Q4 2027.
- Dilution from 403,347 ADSs issued in the royalty certificate repurchase, registered for resale.
- Foreign exchange exposure on USD-denominated cash and intercompany balances.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001956827-26-000022 |
| Document: a6-kpressreleaseq12026fina.htm | 0001956827-26-000022 |
| Document: 0001956827-26-000022-index-headers.html | 0001956827-26-000022 |
| Document: 0001956827-26-000022-index.html | 0001956827-26-000022 |
| Document: 0001956827-26-000022.txt | 0001956827-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 22, 2026 22w ago | 6-K | $126.00 $101.25 | ▼ −19.64% | ▼ −17.69% | $139.00 (+10.32%) |
May 20, 2026 22w ago | 6-K | $126.00 $101.25 | ▼ −19.64% | ▼ −19.98% | $139.00 (+10.32%) |
Apr 20, 2026 27w ago | 6-K | $115.65 $115.65 | · 0.00% | ▼ −4.92% | $139.00 (+20.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers